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ABSTRACT
Background. Surgical resection with curative intent for
giant cell tumor of bone (GCTB) may be associated with
severe morbidity. This interim analysis evaluated reduction
in surgical invasiveness after denosumab treatment in pa-
tients with resectable GCTB.
Methods. Patients with primary or recurrent GCTB, for
whom the initially planned surgery was associated with
functional compromise or morbidity, received denosumab
120 mg subcutaneously every 4 weeks (additional doses on
days 8 and 15 of the first cycle). Planned and actual GCTB-
related surgical procedures before and after denosumab
treatment were reported. Patients were followed for sur-
gical outcome, adverse events, and recurrence following
resection.
Results. Overall, 222 patients were evaluable for surgical
downstaging (54 % were women; median age 34 years).
Lesions (67 % primary and 33 % recurrent) were located in
the axial (15 %) and appendicular skeleton (85 %). At the
data cutoff date, most patients had not yet undergone sur-
gery (n = 106; 48 %) or had a less morbid procedure
(n = 84; 38 %) than originally planned. Median (in-
terquartile range) time on denosumab was 19.5 (12.4–28.6)
months for the 106 patients who had not undergone surgery
and were continuing on monthly denosumab. Native joint
preservation was 96 % (n = 24/25) for patients with plan-
ned joint/prosthesis replacement and 86 % (n = 30/35) for
patients with planned joint resection/fusion. Of the 116
patients who had surgery (median postsurgical follow-up
13.0 [8.5–17.9] months), local recurrence occurred in 17
(15 %) patients.
Conclusion. For patients with resectable GCTB, neoad-
juvant denosumab therapy resulted in beneficial surgical
downstaging, including either no surgery or a less morbid
surgical procedure.
Giant cell tumor of bone (GCTB) is an aggressive, bone
lytic, osteoclastogenic stromal tumor that mainly occurs in
young adults.1,2 It commonly presents as an epiphyseal,
monostotic lytic lesion most often found in the distal fe-
mur, proximal tibia, and distal radius.1 It is characterized
by progressive growth and geographic bone lysis, leading
to cortical bone expansion or dissolution with or without
soft tissue extension. Symptoms generally include pain,
swelling, and impaired mobility and function.1 Local me-
chanical load and joint function compromise are common
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in untreated disease. Rarely, GCTB can undergo malignant
transformation. In addition, 1–4 % of GCTB cases give rise
to pulmonary metastases even when the histologic ap-
pearance remains benign.3
Currently, surgical removal of the lesion remains the
only curative intent treatment for GCTB;4 however, local
recurrence or metastasis can still occur following curative
intent surgery with modern imaging and high-speed bur-
ring.5,6 The most common form of surgical treatment for
GCTB is aggressive local curettage with or without packing
of the defect with bone cement or bone graft and internal
fixation. The aim of this approach is to remove the tumor
while preserving the local functional anatomy, including the
articular joint surface. Varying rates of local recurrence
have been reported after intralesional surgical therapy, and
have led to the suggestion that the use of local adjuvants
such as phenol, peroxide, water, or liquid nitrogen may
further improve local control.7–11 More aggressive surgical
approaches employing wide resection of the involved bone
may be chosen to achieve tumor removal and potentially
decrease the risk of local recurrence, at the cost of greater
functional compromise.7 Major excision and resection of
the involved bone (e.g. amputation, joint resection, or
hemipelvectomy) for advanced GCTB,3 even if some form
of bone or joint reconstruction is possible, is associated with
significant functional deficit or morbidity.12
Denosumab, a monoclonal antibody directed against the
receptor activator of nuclear factor-kappa b ligand
(RANKL), has recently been approved in the United States,
Europe, and Japan for the treatment of adults and skeletally
mature adolescents with GCTB that is unresectable or when
surgical resection is likely to result in severe morbidity.13–15
GCTB has been shown to be pathogenetically driven by
pervasive expression of osteoclastic differentiation signals
by tumor mononuclear stromal cells.16–19 Immunohisto-
chemical and molecular probes have shown that stromal cell
elements of GCTB strongly produce and express
RANKL.17 RANKL appears to play an autocrine role in
lesion development fostering and maintaining osteoclast
formation, activation, and survival,18 resulting in con-
tinuous bone resorption19,20 via activating RANK receptor-
positive osteoclast-like giant cells and their precursors.16,21
Previous results from an open-label, single-arm, phase II
study demonstrated sustained denosumab-induced tumor
responses in patients with GCTB (based on assessment of
histologic or radiologic response).22 Denosumab treatment
produced rapid and substantial suppression of bone turn-
over and significant reduction in the numbers of
multinucleated giant cells seen in post-treatment resection
specimens, as well as a marked reduction in the number
and cross-sectional area of residual mononuclear stromal
cells.17,22 There was a consistent finding of complete or
near complete elimination of RANKL-producing stromal
cells and disappearance of original RANK-positive
multinuclear giant cells, along with the concomitant pro-
duction of osteoid and new woven bone.17,22 These
histopathologic changes correlated with an increase in ra-
diographic density on computed tomography scanning.22
An initial planned interim analysis of the first 100 patients
treated with denosumab therapy whose planned surgery
was associated with severe morbidity found that 74 % had
not undergone surgery for GCTB and that 16 % had a
surgical procedure associated with less morbidity.23 At a
median follow-up of 9.2 months (interquartile range [IQR]
4.2–12.9 months), 61 % of patients derived clinical benefit
from denosumab, including pain reduction and improved
mobility and function.23 In this study, we confirm and
extend the results from the initial interim downstaging
analysis23 and report detailed results from an unplanned
interim analysis, performed at regulatory agency request, in
222 denosumab-treated patients with evaluable, resectable
GCTB whose initially planned curative intent surgery was
expected to result in severe morbidity.
METHODS
Patients and Procedures
The study design and inclusion/exclusion criteria for this
open-label, phase II study were previously reported
(ClinicalTrials.gov identifier NCT00680992).23 Briefly,
adults or skeletally mature adolescents (C12 years of age)
weighing C45 kg with radiologic evidence of C1 mature
long bone, histologically confirmed GCTB, radiographically
measurable active disease within 1 year before study en-
rollment, and Karnofsky performance status C50 % were
enrolled. Exclusion criteria included concurrent use of al-
ternative treatments for GCTB; known or suspected
diagnosis of sarcoma, non-GCTB, giant cell–rich tumors,
brown cell bone tumor of hyperparathyroidism, or Paget
disease; diagnosis of a second malignancy in the past
5 years; history or current evidence of osteonecrosis or os-
teomyelitis of the jaw, active dental or jaw problems
necessitating oral surgery, or nonhealed dental or oral sur-
gery; or pregnancy.
Enrolled patients were separated into three cohorts.23
Patients from cohort 2 who were evaluable for surgical
downstaging were included in this analysis. These patients
had planned GCTB surgery that was associated with func-
tional compromise or severe morbidity based on either the
planned procedure, such as joint resection, limb amputation,
or hemipelvectomy, or the extent or location of the lesion.
The study was approved by the independent ethics com-
mittee or institutional review board for each study center. All
patients provided written informed consent. The cutoff date
for the data analysis was 30 August 2013.
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Procedures
Patients received open-label subcutaneous denosumab
120 mg every 4 weeks, with additional doses administered
on days 8 and 15 during the first month of therapy only.
For patients who had complete tumor resection, denosumab
therapy continued for six additional doses after resection.
In all other cases, denosumab therapy continued per pro-
tocol until either disease progression, recommendation of
discontinuation by the investigator or sponsor, absence of
clinical benefit according to the investigator’s judgment,
withdrawal of patient consent, pregnancy, or use of any
proscribed treatments. All patients were strongly advised to
take daily supplements of C500 mg calcium and C400 IU
vitamin D.
Curative intent surgical procedures planned at study entry
were recorded prospectively, and actual surgical procedures
performed after denosumab treatment were reported by in-
vestigators. Procedure selection and timing were based on
serial review of radiographic imaging and clinical response
by the treating physician. Disease status and clinical benefit
(investigator-determined, every 4 weeks) were based on
physical examination, patient report of symptoms, and serial
radiologic imaging assessment per local standard practice.
Serial radiographic assessments24,25 of GCTB lesions were
performed per local practice guidelines, and the recom-
mended surgical intervention was provided; the procedure
was ranked using an invasiveness and postsurgical func-
tional deficit scale.12,24 The initially recommended surgeries
ranged from curettage to hemipelvectomy (invasive-
ness/postoperative functional impairment scale detailed in
electronic supplementary Table S1).
Safety Assessment
Adverse events (AEs) and serious AEs (SAEs) were
recorded and graded according to National Cancer Institute
Common Terminology Criteria for Adverse Events (CTCAE)
version 3.0.23.26
Statistical Analysis
Statistical analyses were descriptive in nature, and only
summary statistics were presented. Efficacy and safety analyses
included patients who enrolled, received at least one dose of
denosumab, and were evaluable for surgical downstaging. No
formal sample size calculations were undertaken. Descriptive
statistics included median (IQR) as appropriate for continuous
variables, and frequency (%) for categorical variables.
RESULTS
Baseline demographics and disease characteristics of
patients in our cohort are shown in Table 1 and Fig. 1. Of
the 222 patients enrolled and evaluable for surgical
downstaging, 54.1 % (n = 120) were female and 80.2 %
(n = 178) were white. The median (IQR) age was 34 (25–
44) years. The lesions were in the lower (52.7 %; n = 117)
and upper (27.9 %; n = 62) extremities or axial skeleton
(14.9 %; n = 33). The majority (66.7 %; n = 148) of pa-
tients presented with primary GCTB, and 33.3 % (n = 74)
of patients had a recurrent tumor following a previous
curative intent surgical procedure.
Exposure and Treatment Duration
As of the cutoff date for this analysis, the 222 patients
enrolled in this surgical downstaging cohort were treated
with denosumab for a median (IQR) duration of 15.3
(12.1–23.6) months. In the 106 patients who had not yet
had surgery and continued on monthly denosumab per












Female 80 (54.1) 40 (54.0) 120 (54.1)
Male 68 (45.9) 34 (46.0) 102 (45.9)
Race/ethnicity, n (%)
White 117 (79.1) 61 (82.4) 178 (80.2)
Asian 10 (6.8) 4 (5.4) 14 (6.3)
Hispanic 10 (6.8) 3 (4.1) 13 (5.9)
Black 8 (5.4) 4 (5.4) 12 (5.4)
Other 3 (2.0) 2 (2.7) 5 (2.3)
Age, years, median
(Q1, Q3)
34 (26, 43) 35
(25, 46)
34 (25, 44)
GCTB presentation status, n (%)
Primary 148 – 148 (66.7)
Recurrent – 74 74 (33.3)
Planned surgery at presentation, n (%)b
Hemipelvectomy 10 (6.8) 0 10 (4.5)
Amputation 21 (14.2) 17 (23.0) 38 (17.1)
Joint/prosthesis
replacement
17 (11.5) 8 (10.8) 25 (11.3)
Joint resection/fusion 22 (14.9) 11 (14.9) 33 (14.9)
En bloc resection 57 (38.5) 26 (35.1) 83 (37.4)
En bloc excision 4 (2.7) 4 (5.4) 8 (3.6)
Marginal excision 1 (0.7) 0 1 (\1.0)
Curettage 9 (6.1) 8 (10.8) 17 (7.7)
Other 7 (4.7) 0 7 (3.2)
GCTB giant cell tumor of bone, Q1, Q3 quartile 1, quartile 3
a Patients evaluable for surgical downstaging
b Percentages may not add up to 100 due to rounding
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protocol, a median (IQR) of 22.5 (15.0–34.0) doses of
denosumab were administered for a median of 19.5 (12.4–
28.6) months (electronic supplementary Fig. S1, Panel A).
In the 116 patients who underwent surgery, the median
(IQR) duration of denosumab treatment was 14.2 (12.0–
17.7) months (electronic supplementary Fig. S1, Panel B).
Treatment with denosumab resulted in radiologic evidence
of an arrest in bone lysis and the interval development of
new intralesional calcification (measured as increasing
density [average Hounsfield unit density] on computed
tomography), increases in cortical bone thickness (includ-
ing the reappearance of cortical integrity), and an overall
reduction in GCTB lesion size (measured in terms of
longest measured lesion diameter) [example radiographs
shown in Fig. 2].
Planned Versus Performed Surgery
In this cohort of patients, most had either not yet un-
dergone surgery (48 %; n = 106/222) and remained on
denosumab therapy or had undergone a less morbid pro-
cedure than originally planned (38 %; n = 84/222;
Table 2). High morbidity procedures were avoided in 80 %
of patients with either a planned hemipelvectomy (n = 8/
10) or planned amputation (n = 32/40). Eighty-eight per-
cent (n = 7/8) of patients with a planned en bloc excision
and 37 % (n = 31/85) of patients with a planned en bloc
resection were managed without surgical intervention in
the reported follow-up period. Of the 85 patients with a
planned en bloc resection, 85 % (n = 71) were able to
have a less invasive or bone excision–sparing procedure or
no surgery at all. The native joint preservation rate was
96 % (n = 24/25) in patients with a planned joint/pros-
thesis replacement and 86 % (n = 30/35) in patients with a
planned joint resection/fusion. Of the 18 patients with
planned curettage at baseline, 44 % (n = 8) required no
surgery, 39 % (n = 7) underwent curettage as planned, and
17 % (n = 3) required en bloc resection.
Procedures associated with a higher surgical morbidity
were performed in six cases on study that were not planned
at study entry. There were three cases in which curettage
was planned and an en bloc resection was performed: two
cases with lesions located in vertebral bodies, associated
with significant soft tissue extension and bony destruction
involving adjoining ribs with significant spinal cord com-
pression, and one case with a rapidly growing 7-cm mass
that originated in the posterior iliac spine but displayed
evidence of cortical break and had invaded the paraverte-
bral and psoas muscles extensively. For the remaining three
cases, there was one case each in which an en bloc excision
was planned and an en bloc resection was performed
(proximal tibia lesion that had recurred twice before re-
ferral for trial enrollment), an en bloc resection was
planned and a joint/prosthesis replacement was performed
(recurrent proximal tibia lesion that had been resected
13 months previously with placement of hardware), and a
n=222/106 
Baseline bone location and count for 










Calcaneus 3/2 Talus 2/1 





Pelvis (incl. ilium, ischium) 20/11
50% lesions remain on treatment 
where initial n>2 
Midhand (metacarpal, carpal) 6/4
FIG. 1 Giant cell tumor of bone lesion location at baseline and operative status. Lesion locations highlighted in blue show sites where C50 % of
patients remain on denosumab without curative intent surgery
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marginal excision was planned and an amputation per-
formed (proximal first phalanx lesion with radiographic
evidence of involvement of the articulating distal meta-
carpal head).
This cohort study is remarkable in that 33 % of patients
who enrolled had already had one or more local recur-
rences after failed primary curative intent surgery. The
patients with locally recurrent GCTB had very similar re-
sults to those seen in the primary GCTB population.
Specifically, 45 (61 %) had not yet undergone surgery at
the data cutoff date, 17 (23 %) underwent a less morbid
procedure, 10 (14 %) underwent surgery as planned, and
only 2 (3 %) underwent a more invasive morbid procedure.
Importantly, of 17 initially recommended amputations in
the locally recurrent population, none were required to date
(see outcomes in patients following local recurrence in
electronic supplementary Table S2).
Median (IQR) duration of postoperative follow-up for
all patients (n = 116) who underwent curative intent sur-
gery was 13.0 (8.5–17.9) months. Local recurrence was
reported in 15 % (n = 17/116) of patients who had sur-
gery. The median duration of postoperative time until
recurrence in the 17 patients who experienced local re-
currence was 13.6 (10.5–15.7) months. In the 99 patients
who underwent surgery but had not experienced recurrence
by the time of data cutoff, the median postoperative follow-
up time was 12.9 (7.8–18.0) months (see electronic sup-
plementary Fig. S2). Of the 17 patients with local
recurrence following denosumab therapy, 14 underwent
curettage as their initial on-study GCTB surgery, 2
Before Denosumab After Denosumab
a b
c d
FIG. 2 Example of radiographic
images of giant cell tumor of bone of
the proximal humerus and distal femur
before (a, c) and after (b, d) denosumab
therapy. The initial lesions were
expansile with a thin peripheral
calcified shell and primarily soft tissue
density centrally (a) and showed
extensive soft tissue displacement with
progression following radiotherapy 2
years previously (c). After 4 months of
treatment with denosumab, the
peripheral calcification was thicker, the
central lesion more heavily
mineralized, and the overall size was
slightly decreased (b, d)
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underwent en bloc resection, and 1 had a joint resection.
The median number of doses of denosumab given in the
adjuvant setting per protocol was 6.0 (IQR 3.0–6.0). Local
recurrence was reported in 5 of the 29 patients (17 %) with
recurrent GCTB at enrollment who underwent surgery after
on-study treatment with denosumab.
Adverse Events
AEs of any grade occurring with[10 % frequency were
as follows: arthralgia (24.8 %), fatigue (20.7 %), pain in
extremity (19.4 %), headache (18.9 %), nausea (18.0 %),
and back pain (10.8 %). Grade 3 or 4 AEs occurring with a
C1 % frequency were hypophosphatemia (2.7 %) and pain
in extremity (1.4 %). Twenty-one (9.5 %) patients experi-
enced SAEs, and nine (4.1 %) experienced AEs that
resulted in treatment discontinuation (Table 3). Of the
21 SAEs reported by investigators, only two occurred
more frequently than once (appendicitis and osteitis;
both n = 2, 0.9 %). There was one case each of
osteonecrosis, nondisplaced tibia fracture, back pain, other
neoplasm, and myeloproliferative disorder. Four (1.8 %)
patients were reported with malignant GCTB transforma-
tion on study: two within-field, radiation-associated
sarcomatous transformations at 4 and 6 years after radio-
therapy, respectively, and two with pelvic or sacral GCTB
lesions that progressed on denosumab by 257 days of ex-
posure. In each of these latter two cases, a diagnosis of
primary malignant GCTB was felt by the investigator to
have been missed by sampling error at initial core biopsy.
Nonserious occurrences of hypocalcemia were observed in
3.2 % of patients; no serious occurrences were reported.
Only one patient reported osteonecrosis of the jaw
(CTCAE grade 1), which resolved by the data cutoff date.
DISCUSSION
Among patients with resectable GCTB treated with
denosumab and for whom curative intent surgery was
planned and believed to be associated with significant
morbidity before enrollment, 48 % had not yet undergone
surgery altogether and remained on monthly denosumab
treatments at the time of the data cutoff. Another 38 % of
patients were treated with denosumab and underwent a less
invasive surgical procedure than was planned at study en-
try. The patients who underwent a curative intent procedure
while on study have not yet experienced an increased local
recurrence rate (15 %, at a median postoperative follow-up
TABLE 2 Planned versus actual surgery in the study cohort (N = 222)

























8 (80.0) 1 (10.0) – – – – 1 (10.0) – 
Amputation 
(n=40)  








14 (40.0) 14 (40.0) – – 2 (5.7) 5 (14.3) – – 
En bloc resection 
(n=85)  
31 (36.5) 39 (45.9) 1 (1.2) – 13 (15.3) – 1 (1.2) – 
En bloc excision 
(n=8)  
7 (87.5) – – – 1 (12.5) – – – 
Marginal excision 
(n=1)  
0 – – – – – – 1 (100.0) 
Curettage 
(n=18)  
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of 13.0 months for the 116 patients who underwent sur-
gery) or rebound effect following discontinuation of
denosumab treatment. These results support the conclusion
that denosumab therapy may represent an important option
for patients with resectable GCTB to avoid immediate
surgery, control disease, or achieve equivalent surgical
outcomes with less morbid procedures.
For patients with resectable GCTB tumors, disease
control can be achieved with wide surgical excision or less
invasive intralesional curettage. GCTB is usually surgically
treated with intralesional curettage combined with high-
speed burring, which is the least invasive surgical option,
improving the thoroughness of tumor removal and allowing
preservation of the joint adjacent to the tumor. Recurrence
rates associated with intralesional curettage using bone
graft as void filler and no additional adjuvants (such as
cryotherapy or phenol) are reported to be between 12 and
65 %.25,27–33 Although wide excision is associated with a
lower risk of local recurrence (up to 12 %),25,27,28,30,34 it is
necessarily associated with poorer long-term functional
consequences due to greater bone loss and the limitation of
joint motion due to resection reconstruction. In view of
these risks, deferring surgery or downstaging the surgical
procedure needed to treat GCTB may offer substantial
clinical benefits to patients.
Denosumab may permit less invasive procedures for
patients with GCTB without deleterious outcomes, possi-
bly serving as a contrast to previous reports indicating that
highly morbid procedures are required to limit disease
progression and recurrence.25,33,35,36 The native joint
preservation was [85 % in patients with planned joint/
prosthesis replacement or joint resection/fusion with
denosumab treatment. In addition, even in cases where
prosthetic replacement was performed, reduction in the size
of the tumor mass and bone healing around the periphery of
the tumor can facilitate complete en bloc tumor resection.
Furthermore, there are several patients in the study in
whom highly invasive surgery (e.g. amputation,
hemipelvectomy, or axial skeleton surgery) was planned
who remained on treatment with denosumab after achiev-
ing disease control, thus far without the need for highly
invasive surgical intervention.
Recurrence rates in this study following surgical resection
were similar to published experience (between 12 and
65 %25,27–33), which is particularly notable given the loca-
tion of the tumors in our cohort, as well as the number of
patients (n = 74; 33.3 %) with recurrent disease. These
findings suggest that downstaging of the surgical invasive-
ness in patients treated with denosumab has not given rise to
an increase in recurrence rate at a median postoperative
follow-up of 13.0 months. Although these data must be in-
terpreted with some caution given the follow-up time,
previous collaborative group studies34 and longitudinal in-
stitutional case series9,31 have shown that local recurrence
following surgery tends to occur predominantly within the
first postoperative 12–18 months. No new safety risks were
observed in this population of patients with GCTB receiving
denosumab therapy. Osteonecrosis of the jaw, as well as
hypocalcemia, were observed at low rates, consistent with
previous studies of denosumab.23 Additional protocol-di-
rected follow-up time of these patients (for 60 months total
following surgery) will continue to reveal whether surgical
downstaging modifies the long-term risk of postsurgical lo-
cal recurrences in this population.
We report six cases in which procedures associated with
a higher surgical morbidity that were not planned at study
entry were performed on study. In each of these cases, the
patient experienced radiographic response (defined as a
reduction in size and/or increase in calcification), clinical
benefit (defined as a reduction in pain and/or improvement
in function or mobility), or both. Aside from a grade 3
wound infection in the patient who underwent resection of
his iliac lesion, there were no reported intraoperative or
postoperative surgical complications, and none of these six
TABLE 3 Patients with adverse eventsa
Patients with AEs Study cohort (N = 222)
[n (%)]
Overall safety summary 193 (86.9)
AEs occurring with[10 % frequency
Arthralgia 55 (24.8)
Fatigue 46 (20.7)
Pain in extremity 43 (19.4)
Headache 42 (18.9)
Nausea 40 (18.0)
Back pain 24 (10.8)
Grade 3 or 4 AEs 33 (14.9)
Hypophosphatemiab 6 (2.7)
Pain in extremityb 3 (1.4)
Serious AEs 21 (9.5)
AEs leading to treatment discontinuation 9 (4.1)
AEs of interest
Hypocalcemia (nonserious) 7 (3.2)
Serious infections 6 (2.7)




a Based on Medical Dictionary for Regulatory Activities, version
14.1, and Common Terminology Criteria for Adverse Events, version
3.0
b Hypophosphatemia and pain in extremity were the only grade 3 or 4
AEs occurring with a frequency C1 %
c One case of osteonecrosis of the jaw resolved by the cutoff date
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patients had experienced local or distant recurrence at the
time of the data cutoff.
CONCLUSIONS
As of the cutoff date for this interim analysis, treatment
with denosumab decreased the need for surgical interven-
tion and reduced surgical morbidity in patients with GCTB
who underwent surgery with curative intent. These findings
support the use of denosumab in a preoperative setting to
defer or downstage the planned surgical procedure in pa-
tients with GCTB when surgical resection is likely to result
in severe morbidity.
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